SF3769 would have permanently prohibited pharmaceutical manufacturers from restricting the delivery of discounted prescription drugs to qualifying hospitals, clinics, and pharmacies participating in the federal 340B Drug Pricing Program. The bill would have removed the July 1, 2027 expiration date for existing state restrictions, and classified violations as unfair or deceptive trade practices, allowing the Minnesota attorney general to pursue enforcement actions against manufacturers.

The Minnesota State Senate passed SF3769 on April 7, 2026 by a vote of 42 to 24. We have assigned pluses to the nays because states should not support any programs that lack authorization under Article I, Section 8 of the U.S. Constitution. By forcing private drug manufacturers to comply with mandates that interfere with their freedom to contract, protected under Article I, Section 10, this bill violates constitutional safeguards, undermines federalism, and erodes free-market principles. SF3769 entrenches an unconstitutional federal welfare program and expands government interference in healthcare.